High Court Will Consider Whether Reverse-Payment Settlements Are Anti-Competitive

High Court Will Consider Whether Reverse-Payment Settlements Are Anti-Competitive

WASHINGTON, D.C. - The Supreme Court today granted the Federal Trade Commission's petition for a writ of certiorari seeking consideration of whether reverse-payment settlements of patent litigation between the holder of a drug patent and generic manufacturers of the drug violate federal antitrust law (Federal Trade Commission v. Watson Pharmaceuticals, Inc., et al., No. 12-416, U.S. Sup.).

Find full version on lexis Advance®
Access this news story on lexis.com®